Abstract
Analytical concerns within hemostasis and thrombosis testing are continuously decreasing. This is essentially attributable to modern instrumentation, improvements in test performance and reliability, as well as the application of appropriate internal quality control and external quality assurance measures. Pre-analytical issues are also being dealt with in some newer instrumentation, which are able to detect hemolysis, icteria and lipemia, and, in some cases, other issues related to sample collection such as tube under-filling. Post-analytical issues are generally related to appropriate reporting and interpretation of test results, and these are the focus of the current overview, which provides a brief description of these events, as well as guidance for their prevention or minimization. In particular, we propose several strategies for improved post-analytical reporting of hemostasis assays and advise that this may provide the final opportunity to prevent serious clinical errors in diagnosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- APCR:
-
Activated protein C resistance
- aCL:
-
Anticardiolipin antibody (assay)
- aPL:
-
Antiphospholipid antibody
- APS:
-
Antiphospholipid (antibody) syndrome
- APTT:
-
Activated partial thromboplastin time
- AT:
-
Antithrombin
- dRVVT:
-
Dilute Russell viper venom time
- FVL:
-
Factor V Leiden
- KCT:
-
Kaolin clotting time
- LA:
-
Lupus anticoagulant
- PC:
-
Protein C
- PS:
-
Protein S
- VKA:
-
Vitamin K antagonist
- VWF:
-
von Willebrand factor
- VWD:
-
von Willebrand disease
References
Favaloro EJ, Lippi G, Adcock DM (2008) Preanalytical and postanalytical variables: the leading causes of diagnostic error in haemostasis? Semin Thromb Hemost 34:612–634
Favaloro EJ, Funk (Adcock) DM, Lippi G (2012) Preanalytical variables in coagulation testing associated to diagnostic errors in hemostasis. Lab Med 43:54–60
Adcock DM, Favaloro EJ, Lippi G (2016) Critical pre-examination variables in the hemostasis laboratory and their quality indicators. Clin Biochem 49:1315–1320
Lippi G, Guidi GC (2007) Risk management in the preanalytical phase of laboratory testing. Clin Chem Lab Med 45:720–727
Coppola A, Tufano A, Cerbone AM, Di Minno G (2009) Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism. Semin Thromb Hemost 35:683–694
Favaloro EJ, Bonar R, Duncan E et al (2007) Misidentification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 39:504–511
Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K (2015) The effect of dabigatran on haemostasis tests: a comprehensive assessment using in-vitro and ex-vivo samples. Pathology 47:355–364
Favaloro EJ, Lippi G (2015) Laboratory testing in the era of direct or non-vitamin k antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost 41:208–227
Lippi G, Favaloro EJ (2015) Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med 53:185–197
Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K (2016) The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 48:60–71
Favaloro EJ, Lippi G (2017) Interference of direct oral anticoagulants (DOACs) in hemostasis assays: high potential for diagnostic false positives and false negatives. Blood Transfus 7:1–4
Favaloro EJ, McDonald D, Lippi G (2009) Laboratory investigation of thrombophilia: the good, the bad and the ugly. Semin Thromb Hemost 35:695–710
Favaloro EJ, Orsag I, Bukuya M, McDonald D (2002) A nine-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. Pathology 34:348–355
Favaloro EJ, Facey D, Grispo L (1995) Laboratory assessment of von Willebrand Factor: use of different assays can influence the diagnosis of von Willebrand’s disease, depending on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. Am J Clin Pathol 104:264–271
Favaloro EJ, Bonar RA, Mohammed S et al (2016) Type 2M von Willebrand disease—more often misidentified than correctly identified. Haemophilia 22:e145–e155
Favaloro EJ, Bonar RA, Meiring M, Duncan E, Mohammed S, Sioufi J, Marsden K (2014) Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 134:393–403
Favaloro EJ (2008) Clinical utility of the PFA-100. Semin Thromb Hemost 34:709–733
Favaloro EJ (2017) Clinical utility of closure times using the Platelet Function Analyzer (PFA)-100/200. Am J Hematol 92:114–118
Lippi G, Franchini M, Brocco G, Manzato F (2001) Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost 85:369–370
Favaloro EJ, Wong RCW (2008) Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Haemost 34:389–410
Favaloro EJ, Wong RCW (2014) Antiphospholipid antibody testing for the antiphospholipid syndrome: a synopsis of challenges and recent guidelines. Pathology 46:481–495
Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG (2009) Official communication of the scientific and standardization committee on lupus anticoagulant/phospholipid-dependent antibodies: update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 7:1737–1740
Plebani M (1999) The clinical importance of laboratory reasoning. Clin Chim Acta 280:35–45
Lippi G, Franchini M, Targher G, Favaloro EJ (2008) Help me, Doctor! My D-dimer is raised. Ann Med 40:594–605
Plebani M (2004) What information on quality specifications should be communicated to clinicians, and how? Clin Chim Acta 346:25–35
Plebani M (2009) Interpretative commenting: a tool for improving the laboratory-clinical interface. Clin Chim Acta 404:46–51
Favaloro EJ, Lippi G (2010) Laboratory reporting of haemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis? Clin Chem Lab Med 48:309–321
Lippi G, Tripodi A, Simundic AM, Favaloro EJ (2015) International survey on d-dimer test reporting: a call for standardization. Semin Thromb Hemost 41:287–293
Longstaff C, Adcock D, Olson JD et al (2016) Harmonisation of D-dimer—a call for action. Thromb Res 137:219–220
Lippi G, Mattiuzzi C (2016) Critical laboratory values communication: summary recommendations from available guidelines. Ann Transl Med 4:400
Lippi G, Favaloro EJ (2016) Reflections on the next generation of hemostasis instrumentation. A glimpse into the future? J Lab Med Laboratoriums Medizin. doi:10.1515/labmed-2015-0087
Lippi G, Plebani M, Favaloro EJ (2015) The changing face of hemostasis testing in modern laboratories: consolidation, automation, and beyond. Semin Thromb Hemost 41:294–299
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Favaloro, E.J., Lippi, G. (2017). Post-analytical Issues in Hemostasis and Thrombosis Testing. In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_40
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7196-1_40
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7194-7
Online ISBN: 978-1-4939-7196-1
eBook Packages: Springer Protocols